title: Successful therapeutic use of a single-dose of rituximab on relapse in adults with minimal change nephrotic syndrome.
abstract: Minimal change nephrotic syndrome (MCNS) usually is considered to have a good renal prognosis, but the frequency of relapses is a therapeutic challenge to physicians. The treatment of patients with multiple relapses remains a matter of controversy, because few controlled studies are available. We report the case of a 25-year-old man who experienced relapses of MCNS. Single-dose rituximab therapy (total dose 500 mg) was given during the fourth relapse. Complete remission occurred 10 days later, when no CD19/20-positive B cells were detected in the blood. This the first report of efficacy of single-dose rituximab therapy to treat multi-relapsing MCNS in an adult patient.
authors.affiliation: Department of Medicine, Kidney Center, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Sawara
authors.forename: M
authors.initials: M
authors.lastname: Itabashi
authors.forename: C
authors.initials: C
authors.lastname: Kojima
authors.forename: H
authors.initials: H
authors.lastname: Tabata
authors.forename: D
authors.initials: D
authors.lastname: Kamei
authors.forename: K
authors.initials: K
authors.lastname: Kawanishi
authors.forename: T
authors.initials: T
authors.lastname: Moriyama
authors.forename: H
authors.initials: H
authors.lastname: Sugiura
authors.forename: M
authors.initials: M
authors.lastname: Tsukada
authors.forename: T
authors.initials: T
authors.lastname: Takei
authors.forename: T
authors.initials: T
authors.lastname: Ogawa
authors.forename: T
authors.initials: T
authors.lastname: Yoshida
authors.forename: J
authors.initials: J
authors.lastname: Arai
authors.forename: K
authors.initials: K
authors.lastname: Uchida
authors.forename: K
authors.initials: K
authors.lastname: Tsuchiya
authors.forename: K
authors.initials: K
authors.lastname: Nitta
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage*; D008297:Male; D009402:Nephrosis, Lipoid / Q000188:drug therapy*; D012008:Recurrence; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab